Diabetes Care 2003
You may adjust the dosage according to the type of peptide, response, and objectives
There is emerging evidence that this may work for selected patients under supervision
The model included the following covariates: age, most recent hemoglobin A1c (if available), overweight/obesity status, body mass index (BMI), hypertension, ischemic heart disease, obstructive sleep apnea, hyperlipidemia, hypercholesterolemia, and prior therapy with antidiabetic agents (including sodium-glucose cotransporter 2 (SGLT2) inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, thiazolidinediones, alpha-glucosidase inhibitors, sulfonylureas, metformin, insulins, and other blood glucose-lowering drugs), as shown in Supplementary Table 1
Results Baseline data and target value The results revealed that the percentage of rational injectable PPI use from November to December 2023 (before team implementation) was 66.51% (baseline value)
As an initial test of the ability of 6-AH family members to alter HGF-dependent cellular activity we evaluated the capacity of several members of the family to modify the proliferative activity of Madin-Darby canine kidney (MDCK) cells, a standard cellular model for investigating the HGF/Met system (Stella and Comoglio, 1999)
